> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel to Discuss Drug Renal Impairment Evaluations
- URL: https://www.fdaweb.com/panel-to-discuss-drug-renal-impairment-evaluations/
- Published: 2019-04-08T12:00:00.000Z
- Updated: 2026-09-15T01:18:57.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5143810

*Federal Register* notice: FDA has announced a 5/7 Pharmaceutical Science and Clinical Pharmacology Advisory Committee meeting. Panel members are scheduled to discuss approaches to evaluate the effect of renal impairment on drug exposure, and best practice considerations for translating pharmacokinetic (PK) information into dose individualization instructions. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2019-04-08/pdf/2019-06900.pdf?ref=fdaweb.com).